Zansecimab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Zansecimab for COVID-19

1 study with 95 patients

Serious outcome risk

Zansecimab

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Zansecimab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−36%

Mortality (1)−36%

RCTs (1)−36%

Late (1)−36%

00.511.5+

← Zansecimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Zansecimab (LY3127804) is an intravenous monoclonal antibody that targets Angiopoietin-2 (Ang-2), a key protein in vascular inflammation.


Jan 31 2022	Jones et al., Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484221119316	Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19
Jan 31 2022	36% higher mortality (p=0.58) and 70% higher combined mortality/intubation (p=0.28). RCT 95 hospitalized patients with COVID-19 pneumonia showing no significant differences with zansecimab (LY3127804, anti-Angiopoietin-2 antibody).